A case report of familial dyskeratosis congenital. Case report
- Authors: Luchkin A.V.1, Mikhailova E.A.1, Fidarova Z.T.1, Troitskaya V.V.1, Galtseva I.V.1, Kovrigina A.M.1, Glinkina S.A.1, Dvirnyk V.N.1, Raykina E.V.2, Pavlova A.V.2, Demina I.A.2, Parovichnikova E.N.1
-
Affiliations:
- National Research Center for Hematology
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Issue: Vol 93, No 7 (2021)
- Pages: 818-825
- Section: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/76357
- DOI: https://doi.org/10.26442/00403660.2021.07.200955
- ID: 76357
Cite item
Full Text
Abstract
Dyskeratosis congenita (DC) is a hereditary syndrome of bone marrow failure, which develops because of telomeres’ defects and combines with cancer predisposition. Its classical clinical features are skin pigmentation, nail dystrophy, oral leukoplakia (“skin-mucosa triad”). The goal is to describe the algorithm of diagnosis, clinical specificities of DC and specific treatment for cases of DC in one family. The present report includes descriptions of diagnosis and treatment of family members diagnosed for the first time as having a DC. The report shows an importance of all diagnostic stages: from a medical history and clinical picture to an application of modern high-tech diagnostic methods (flow-FISH, NGS). The report underlines an importance of diagnosis of all family members for excluding an asymptomatic form after a case of DC has been already detected in that family. A high frequency of a toxicity and secondary neoplasia makes it necessary to realize an individual approach at treatment of each patient with DC (the earliest start of androgen treatment, prompt decision of implementation of allogenic hematopoietic stem cell transplantation). The knowledge of pathogenesis, clinical features and principles of diagnosis and therapy of this disease is relevant to pediatricians and hematologists.
Full Text
##article.viewOnOriginalSite##About the authors
Anton V. Luchkin
National Research Center for Hematology
Author for correspondence.
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-4400-4711
врач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения
Russian Federation, MoscowElena A. Mikhailova
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-2449-2682
д-р мед. наук, проф., вед. науч. сотр. отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения
Russian Federation, MoscowZalina T. Fidarova
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0003-0934-6094
канд. мед. наук, зав. отд-нием химиотерапии гемобластозов и депрессий кроветворения с дневным стационаром
Russian Federation, MoscowVera V. Troitskaya
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-4827-8947
канд. мед. наук, зам. дир. по лечебной работе, зав. отд-нием высокодозной химиотерапии гемобластозов и депрессий кроветворения
Russian Federation, MoscowIrina V. Galtseva
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-8490-6066
канд. мед. наук, зав. лаб. иммунофенотипирования клеток крови и костного мозга
Russian Federation, MoscowAlla M. Kovrigina
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-1082-8659
д-р биол. наук, зав. патологоанатомическим отд-нием
Russian Federation, MoscowSvetlana A. Glinkina
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-7321-1728
врач-патологоанатом патологоанатомического отделения
Russian Federation, MoscowValentina N. Dvirnyk
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-9877-0796
канд. мед. наук, зав. централизованной клинико-диагностической лаб.
Russian Federation, MoscowElena V. Raykina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-7634-2053
канд. мед. наук, зав. лаб. молекулярной биологии
Russian Federation, MoscowAnna V. Pavlova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-3974-5662
мл. науч. сотр. лаб. молекулярной биологии
Russian Federation, MoscowIrina A. Demina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0002-4317-2094
канд. биол. наук, врач клинической лабораторной диагностики лаб. клеточной иммунологии и иммуногенеза
Russian Federation, MoscowElena N. Parovichnikova
National Research Center for Hematology
Email: a_luchkin@rambler.ru
ORCID iD: 0000-0001-6177-3566
д-р мед. наук, зав. отд-нием химиотерапии гемобластозов, депрессий кроветворения и ТКМ
Russian Federation, MoscowReferences
- Карпова Н.С., Абдулкадыров K.M., Селиванов Е.А., Балашова В.A. Современные представления о роли теломер и теломеразы в патогенезе гематологических и онкологических заболеваний. Рос. биомед. журн. 2012;13(1):38-57 [Karpova NS, Abdulkadyrov KM, Selivanov EA, Balashova VA. The modern conception of the proper role of telomeres and telomerase in pathogenesis of hematologic and oncology diseases. Russian biomedical journal. 2012;13(1):38-57 (in Russian)].
- Hashmi SK, Allen C, Klaassen R, et al. Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype–phenotype correlation. Clinical genetics. 2011;79(5):448-58. doi: 10.1111/j.1399-0004.2010.01468.x
- Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103(1):30. doi: 10.3324/haematol.2017.178111
- Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110(4):768-79. doi: 10.1046/j.1365-2141.2000.02109.x
- Ершов Н.М., Овсянникова Г.С., Хачатрян Л.А., и др. Врожденный дискератоз: анализ клинических случаев. Педиатрия. Журн. им. Г.Н. Сперанского. 2014;93(6):90-5 [Ershov NM, Ovsyannikova GS, Khachatryan LA, et al. Congenital dyskeratosis: analysis of clinical cases. Pediatriya. Zhurnal im. GN Speranskogo. 2014;93(6):90-5 (in Russian)].
- Емельянова Т.А., Хмелевская И.Г., Миненкова Т.А., и др. Врожденный дискератоз: клиническое наблюдение. Курский науч.-практ. вестн. «Человек и его здоровье». 2018;(2):44-8 [Emelianova TA, Khmelevskaya IG, Minenkova TA, et al. Congenital dysceratosis: clinical observation. Kursk Scientific and Practical Bulletin “Man and His Health”. 2018;(2):44-8 (in Russian)]. doi: 10.21626/vestnik/2018-2/07
- Нечаевских В.И., Зинина Е.Е., Попова Н.Б. Врожденный дискератоз: клиническое наблюдение. Здравоохранение Югры: опыт и инновации. 2018;4 [Nechaevsky VI, Zinina EE, Popova NB. Congenital dyskeratosis: a clinical case. Ugra health care: experience and innovations. 2018;4 (in Russian)].
- Savage SA, Alter BP. Dyskeratosis congenital. Hematol Oncol Clin North Am. 2009;23(2):215-31. doi: 10.1016/j.hoc.2009.01.003
- Armanios MY, Chen JJL, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. New Engl J Med. 2007;356(13):1317-26. doi: 10.1056/NEJMoa066157
- Nishio N, Kojima S. Recent progress in dyskeratosis congenital. Int J Hematol. 2010;92(3):419-24. doi: 10.1007/s12185-010-0695-5
- Kim HJ, Kim KJ, Lee KH, et al. Interstitial lung disease in a patient with dyskeratosis congenita. Tuberc Respir Dis. 2013;74(2):70. doi: 10.4046/trd.2013.74.2.70
- Dvorak LA, Vassallo R, Kirmani S, et al. Pulmonary fibrosis in dyskeratosis congenita: report of 2 cases. Hum Pathol. 2015;46(1):147-52. doi: 10.1016/j.humpath.2014.10.003
- Parry EM, Alder JK, Qi X, et al. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011;117(21):5607-11. doi: 10.1182/blood-2010-11-322149
- Glousker G, Touzot F, Revy P, et al. Unraveling the pathogenesis of Hoyeraal–Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol. 2015;170(4):457-71. doi: 10.1111/bjh.13442
- Karremann M, Neumaier-Probst E, Schlichtenbrede F, et al. Revesz syndrome revisited. Orphanet J Rare Dis. 2020;15(1):1-13. doi: 10.1186/s13023-020-01553-y
- Duprey PA, Steger JW. An unusual case of dyskeratosis congenita with intracranial calcifications. J Am Acad Dermatol. 1988;19(4):760-2. doi: 10.1016/s0190-9622(88)80357-8
- Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007;110(5):1439-47. doi: 10.1182/blood-2007-02-075598
- Gutierrez-Rodrigues F, Santana-Lemos BA, Scheucher PS, et al. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PloS one. 2014;9(11):e113747. doi: 10.1371/journal.pone.0113747
- Демина И.А., Семченкова А.А., Кагирова З.Р., Попов А.М. Измерение абсолютной длины теломер методом проточной цитометрии. Вопр. гематологии/онкологии и иммунопатологии в педиатрии. 2019;17(4):68-74 [Demina IA, Semchenkova AA, Kagirova ZR, Popov AM. Flow cytometric measurement of absolute telomere length. Pediatric Hematology/Oncology and Immunopathology. 2019;17(4):68-74 (in Russian)]. doi: 10.24287/1726-1708-0-0-0-1-7
- Bessler M, Du HY, Gu B, Mason PJ. Dysfunctional telomeres and dyskeratosis congenita. Haematologica. 2007;92(8):1009-12. doi: 10.3324/haematol.11221
- Yamaguchi H, Baerlocher, GM, Lansdorp, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003;102(3):916-8. doi: 10.1182/blood-2003-01-0335
- Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New Engl J Med. 2005;352(14):1413-24. doi: 10.1056/NEJMoa042980
- Sousa SR, Mota PC, Melo N, et al. Heterozygous TERT gene mutation associated with familial idiopathic pulmonary fibrosis. Respir Med Case Rep. 2019;26:118-22. doi: 10.1016/j.rmcr.2018.12.005
- Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology. 2011;53(5):1608-17. doi: 10.1002/hep.24217
- Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549-57. doi: 10.1182/blood-2008-12-192880
- Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236-43. doi: 10.1182/blood-2008-09-178871
- Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. New Engl J Med. 2016;374(20):1922-31. doi: 10.1056/NEJMoa1515319
- Khincha PP, Wentzensen IM, Giri N, et al. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol. 2014;165(3):349-57. doi: 10.1111/bjh.12748
- Al-Rahawan MM, Giri N, Alter BP. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenital. Int J Hematol. 2006;83(3);275. doi: 10.1532/ijh97.06030
- García MSF, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med. 2014;5:157. doi: 10.2147/JBM.S47437
- Trautmann K, Jakob C, von Grunhagen U, et al. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia. Thromb Haemost. 2012;108(08):397-8. doi: 10.1160/TH12-02-0121
- Демина И.А., Овсянникова Г.С., Калинина И.И., и др. Значение длины теломер для индивидуализации терапии апластической анемии. Педиатрия. Журн. им. ГН Сперанского. 2017;96(5):97-103 [Demina IA, Ovsyannikova GS, Kalinina II, et al. Telomere length value for individualization of aplastic anemia therapy. Pediatriya named after GN Speransky.2017;96(5):97-103 (in Russian)]. doi: 10.24110/0031-403X-2017-95-5-97-103
- Fioredda F, Iacobelli S, Korthof ET, et al. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018;183(1):110-8. doi: 10.1111/bjh.15495
- Dokal I. Dyskeratosis congenital. Hematology Am Soc Hematol Educ Program. 2011;1:480-6. doi: 10.1182/asheducation-2011.1.480